ClinicalTrials.gg
RecruitingNCT07171281GLYCOTIMEUpdated Sep 29, 2026

Precise Eating Time to Improve Glycemic Control and Cardiometabolic Health in Prediabetes and Diabetes

An interventional study of Early Time-Restricted Eating and Late Time-Restricted Eating in Prediabetes, Type 2 Diabetes and Obesity &Amp; Overweight, sponsored by German Institute of Human Nutrition. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by German Institute of Human Nutrition · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Sep 29, 2026Start date movedSponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Prediabetic State with a site in Germany — 12 open to participants now, 13 under way, 1 of them phase 3. Prediabetic State · Germany.

Planned enrollment
19th of 27
30 · median 60
Started
2025
with 3 others
No phase
19 of 30
7 open now
Primary completion
2027-12
later than 6 of 12 live
Registered
24th of 30
by date
Lead sponsor
6 of 30
German Institute of Human Nutrition

Among the 30 studies in Prediabetic State with a site in Germany, this one is the 19th largest by planned enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2025, is one of 19 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 24th registered.

Prediabetic State

918 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

Browse Prediabetic State studies →

Open to participants now

12 of the 30 studies in Prediabetic State with a site in Germany are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Prediabetic State with a site in Germany, or all of them as a file.
02

Study summary

The objective of this study is to investigate the impact of hypocaloric time-restricted eating (TRE) at different day times (early versus late TRE) on glucose metabolism and other cardiometabolic parameters in individuals with overweight and with normal, or impaired glucose metabolism (prediabetes and type 2 diabetes). In addition, the study aims to elucidate the molecular mechanisms underlying these effects.

Read the detailed description

This dietary intervention study will follow a crossover design. During the intervention phases, participants will restrict their dietary intake to a defined eating window of 8 hours - predominantly in the morning (early TRE) or predominantly in the afternoon (late TRE) - in conjunction with a moderate caloric restriction for five weeks. A 10-12-week washout phase will separate the intervention periods.

Overweight and obese individuals with healthy glucose metabolism, prediabetes, or non-insulin-treated type 2 diabetes will be recruited for the study.

03

Conditions studied

  • Prediabetes
  • Type 2 Diabetes
  • Obesity &Amp; Overweight

Keywords

  • Time-restricted eating
  • Prediabetes
  • Type 2 Diabetes
  • Chrononutrition
  • Glucose metabolism
  • Overweight
  • Obesity
  • Continuous glucose monitoring
  • TRE
  • Prevention and treatment of type 2 diabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overweight or obesity ( 25-40 kg/m²)
  • Healthy glucose metabolism (fasting glucose \<100 mg/dl and glucose after 2 hours OGTT \<140 mg/dl)
  • OR impaired glucose metabolism (fasting glucose 100-125 mg/dl and/or glucose after 2 hours OGTT 140-199 mg/dl and/or 5.7-6.4%)
  • OR type 2 diabetes (according to existing medical diagnosis or fasting glucose >126 mg/dl and/or glucose after 2 hours OGTT >200 mg/dl and/or HbA1c ≥6.5%)
  • Daily eating window ≥12 hours

Exclusion criteria

Exclusion Criteria:

  • Weight changes > 5% within past 3 months
  • Shift work
  • Traveling across more than one time zone within one month prior to the study
  • Pregnancy and breastfeeding
  • Eating disorders, food intolerance/allergy to ingredients in the diet product, vegan diet, practicing time-restricted eating
  • Severe chronic illnesses or other conditions that are incompatible with the planned intervention and examination program (e.g. type 1 diabetes, recent cardiovascular event, malabsorption, cancer in the last two years, etc.)
  • Treatment with insulin, sulfonylureas, and GLP-1 receptor agonists, use (oral, cutaneous, or parenteral), regular intake of melatonin, anticoagulation treatment that cannot be paused
  • Extreme early and extreme late chronotypes
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Early Time-Restricted Eating

    Behavioral: Early Time-Restricted Eating

  • Experimental
    Late Time-Restricted Eating

    Behavioral: Late Time-Restricted Eating

Interventions

  • BehavioralEarly Time-Restricted Eating

    Participants will restrict their eating window (8 hours eating and 16 hours fasting per day) and caloric intake moderately. During the early TRE intervention, participants will primarily consume their meals in the morning. The precise eating window will be defined based on the individual chronotype of the participants. Additionally, participants will be required to reduce their daily caloric consumption by 25%. They will replace one daily meal with a calorie-reduced product to facilitate caloric restriction.

    Also known as: eTRE, early TRE

  • BehavioralLate Time-Restricted Eating

    Participants will restrict their eating window (8 hours eating and 16 hours fasting per day) and caloric intake moderately. During the late TRE intervention, participants will primarily consume their meals in the evening. The precise eating window will be defined based on the individual chronotype of the participants. Additionally, participants will be required to reduce their daily caloric consumption by 25%. They will replace one daily meal with a calorie-reduced product to facilitate caloric restriction.

    Also known as: LateTRE, lTRE

06

What researchers measure

Primary outcomes

  1. Mean 24-hour glucose

    Mean 24-hour glucose assessed by continuous glucose monitoring (CGM)

    Time frame: 5 weeks

Secondary outcomes

  1. Glycemic variability

    Inter- and intraday indices of glycemic variability assessed by CGM

    Time frame: 5 weeks

  2. Glucose levels

    Fasting and postprandial glucose \[mg/dL\] in response to a mixed meal tolerance test

    Time frame: 5 weeks

  3. Insulin levels

    Fasting and postprandial insulin \[mU/L\] in response to a mixed meal tolerance test

    Time frame: 5 weeks

  4. Glucagon levels

    Fasting and postprandial glucagon \[pmol/L\] in response to a mixed meal tolerance test

    Time frame: 5 weeks

  5. Insulin resistance

    Insulin resistance, as assessed by HOMA-IR \[AU\]

    Time frame: 5 weeks

  6. Insulin secretion

    Insulin secretion, as assessed with the insulinogenic index \[AU\]

    Time frame: 5 weeks

  7. Body weight

    Body weight \[kg\], as measured by scale weight

    Time frame: 5 weeks

  8. Body Mass Index (BMI)

    BMI \[kg/m2\], calculated as weight/square height

    Time frame: 5 weeks

  9. Waist and hip circumference

    Waist and hip circumference \[cm\] measured by tape

    Time frame: 5 weeks

  10. Body composition

    Body fat mass and lean mass \[kg\], as measured by bioelectrical impendance analysis (BIA)

    Time frame: 5 weeks

  11. Fasting cholesterol

    Fasting total cholesterol, low-density lipoprotein and high-density lipoprotein cholesterol \[mmol/L\]

    Time frame: 5 weeks

  12. Fasting triglycerides

    Fasting triglycerides \[mmol/L\]

    Time frame: 5 weeks

  13. Blood pressure

    Systolic and diastolic blood pressure \[mm Hg\], as measured by manometer

    Time frame: 5 weeks

  14. Resting energy expenditure

    Resting energy expenditure \[kcal/day\], as assessed by indirect calorimetry

    Time frame: 5 weeks

  15. Gene expresssion in adipose tissue

    RNAseq analysis of subcutaneous adipose tissue samples

    Time frame: 5 weeks

  16. Inflammatory markers in blood and adipose tissue

    Levels of adipokines and inflammatory markers measured in blood samples and subcutaneous adipose tissue samples

    Time frame: 5 weeks

  17. Subjective satiety and hunger sensation

    Satiety and hunger scores assessed using Visual Analog Scales (VAS, with a scale of 1-100, where higher values correspond to stronger satiety/hunger)

    Time frame: 5 weeks

  18. Concentration of satiety and hunger regulating hormones

    Levels of ghrelin and peptide YY (PYY), as measured in blood samples in \[pg/mL\]

    Time frame: 5 weeks

  19. Species and strain-level microbiome changes

    Species and strain-level microbiome changes, as assessed by 16S rRNA gene sequencing of stool samples

    Time frame: 5 weeks

  20. Levels of microbiome-derived metabolites

    Levels of microbiome-derived metabolites measured in stool samples and blood plasma

    Time frame: 5 weeks

  21. Sleep quality

    Sleep quality as assessed by the Pittsburgh Sleep Quality Index (PSQI score, which ranges from 0-21, where higher values correspond to worse sleep quality) and also monitored by an ActiGraph device

    Time frame: 5 weeks

  22. Sleep and wake timing

    Sleep onset and offset assessed by the Pittsburgh Sleep Quality Index (PSQI score, which ranges from 0-21, where higher values correspond to worse sleep quality) and in addition by using a sleep diary

    Time frame: 5 weeks

  23. Internal circadian phase

    Internal circadian phase as assessed using the BodyTime assay in peripheral mononuclear blood cells (PBMCs)

    Time frame: Screening visit (week 0)

  24. Glucagon-like peptide-1 levels

    Fasting and postprandial glucagon-like peptide-1 (GLP-1) in response to a mixed meal tolerance test \[pM\]

    Time frame: 5 weeks

  25. Gastric inhibitory polypeptide

    Fasting and postprandial gastric inhibitory polypeptide (GIP) in response to a mixed meal tolerance test \[pg/mL\]

    Time frame: 5 weeks

  26. Gene expresssion in peripheral mononuclear blood cells (PBMCs)

    RNAseq analysis of clock, metabolic and inflammatory gene expression peripheral mononuclear blood cells (PBMCs)

    Time frame: 5 weeks

  27. Malondialdehyde

    Plasma malondialdehyde \[µmol/L\]

    Time frame: 5 weeks

  28. 3-nitrotyrosine

    Plasma 3-nitrotyrosine \[pmol/mg\]

    Time frame: 5 weeks

  29. Protein carbonyls

    Plasma protein carbonyls \[nmol/mg\]

    Time frame: 5 weeks

  30. 36-item Short Form Health Survey (SF-36) to measure health-related quality-of-life

    Health-related quality-of-life, as assessed by the 36-Item Short Form Health Survey (SF-36, with scores ranging from 0 to 100, with a higher score defining a more favorable health state)

    Time frame: 5 weeks

  31. Satisfaction with the intervention

    Satisfaction with the intervention assessed by a 5-point Likert scale (with 5 representing "Very satisfied" and 1 representing "Very dissatisfied")

    Time frame: 5 weeks

  32. Decision behavior

    Impulsiveness assessed by decision making tasks on computer

    Time frame: 5 weeks

Other outcomes

  1. Physical activity level

    24-h physical activity level (light, moderate, sedentary activity, metabolic equivalent of task) will be monitored by an Actigraph device

    Time frame: 5 weeks

  2. Liver enzyme levels and renal values

    γ-glutamyltransferase (GGT), aspartate aminotransferase (ALT), and alanine aminotransferase (AST), creatinine, urea, uric acid determined in fasting blood samples

    Time frame: 5 weeks

  3. Food intake

    Energy intake \[kcal/day\] assessed by food records

    Time frame: 5 weeks

  4. Macronutrient intake

    Percentage of calories from fat, carbohydrates, protein, and fiber, determined based on dietary records

    Time frame: 5 weeks

  5. Food timing

    Start and stop times of daily eating window and clock time of each daily meal intake assessed by food records

    Time frame: 5 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2027, 26 months after the start.

Of 379 non-industry interventional studies with no phase under Prediabetic State, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's planned 26 months is close to that.

Counting every sponsor, half of 425 studies reached it within 23 months; a quarter within 11 and three quarters within 37.

Start moved once since we started tracking on Sep 25, 2026: Sep 2025 → Oct 2025, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2025
First posted
Sep 12, 2025
StartActual
Oct 1, 2025was Sep 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Feb 28, 2028
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 19, 2025→Oct 1, 2025 (actual)
Sep 29, 2026
Sponsor
Collaborators added: University of Surrey; collaborators removed: University of Surrey, UK
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Start date Sep 19, 2025→Oct 1, 2025 (now actual)
    Sponsor Collaborators added: University of Surrey; collaborators removed: University of Surrey, UK
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07171281
Lead sponsor
German Institute of Human Nutrition
Collaborators
Technische Universität Dresden, University of Surrey, University of Geneva, Switzerland, Technische Universität München, Germany, German Center for Diabetes Research, University of Rovira i Virgili, Spain
Responsible party
Olga Ramich (formerly Pivovarova) (Head of Department Molecular Metabolism and Precision Nutrition, German Institute of Human Nutrition) — Principal investigator
First posted
Sep 12, 2025
Start date
Oct 1, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Sep 29, 2026

Study contacts

Olga Ramich, Prof. Dr.
Contact
olga.ramich@dife.de
+49 33200 882749
Bettina Schuppelius, M.Sc.
Contact
bettina.schuppelius@dife.de
+49 33200 882692

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion